Email this article MANIFESTASI KLINIS DAN LUARAN INFEKSI COVID-19 DENGAN DIABETES MELLITUS
Abstract
Infeksi COVID-19 pada pasien dengan diabetes mellitus dikaitkan dengan manifestasi klinis yang lebih berat dan luaran yang lebih buruk. Studi ini bertujuan untuk mengetahui manifestasi klinis dan luaran COVID-19 pada pasien diabetes mellitus di Pondok Observasi Gelora Joko Samudro, Gresik. Studi ini merupakan studi kohort terhadap pasien COVID-19 tanpa gejala/bergejala ringan dengan diabetes mellitus di Pondok Observasi Gelora Joko Samudro Gresik Agustus 2020-Maret 2021. Kelompok kontrol merupakan pasien COVID-19 tanpa komorbid dengan kesamaan jenis kelamin dan usia. Didapatkan 19 subjek sebagai kelompok diabetes. Kelompok diabetes mellitus memiliki resiko sekitar 6 kali lebih tinggi untuk mengalami gejala dibandingkan dengan kelompok kontrol (HR 6,04 IK95% 1,34-27,2). Dibandingkan dengan kelompok kontrol, kelompok diabetes juga memiliki angka konversi negatif di akhir perawatan lebih rendah (HR 0,061 IK95% 0,013-0,286), rerata durasi peluruhan kuman sekitar 5 hari lebih lama (Selisih Rerata 5,7 IK95% 3,73-7,75) dan rerata durasi rawat inap sekitar 5 hari lebih lama (Selisih Rerata 5,3 IK95% 3,07-7,46). Keterbatasan dalam jumlah sampel mempengaruhi hasil penelitian ini. Diperlukan studi dengan jumlah yang lebih besar dan mencakup pasien dengan gejala sedang/berat untuk hasil yang lebih baik. Pasien dengan diabetes mellitus memiliki manifestasi klinis dan luaran COVID-19 yang lebih buruk dibandingkan dengan pasien tanpa komorbid diabetes mellitus.
Keywords
Full Text:
PDF (Bahasa Indonesia)References
International Diabetes Foundation. 2019. IDF Diabetes Atlas. 9th Ed.
Huang J, Zhu L, Bai X, Jia X, Lu Y, Deng A, et al. 2020. Multidimensional Analysis of Risk Factors for the Severity and Mortality of Patients with COVID-19 and Diabetes. Infect Dis Ther. 9(4):981-1002.
Hamer M, Gale CR, Batty GD. 2020. Diabetes, glycaemic control, and risk of COVID-19 hospitalisation: Population-based, prospective cohort study. Metab Clin Exp. 112(1):1-3.
Fox T, Ruddiman K, Lo KB, Peterson E, DeJoy R, Salacup G, et al. 2021. The relationship between diabetes and clinical outcomes in COVID-19: a single-center retrospective analysis. Acta Diabetol. 58(1):33-38.
Shah H, Khan MSH, Dhurandhar N V, Hegde V. 2021. The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19. Acta Diabetol. 58(7):831-843.
Rajpal A, Rahimi L, Ismail-Beigi F. 2020. Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. J Diabetes. 12(12):895-908.
Han M, Ma K, Wang X, Yan W, Wang H, You J, et al. 2021. Immunological Characteristics in Type 2 Diabetes Mellitus Among COVID-19 Patients. Front Endocrinol (Lausanne). 12(3):1-12.
Cheng Y, Yue L, Wang Z, Zhang J, Xiang G. 2021. Hyperglycemia associated with lymphopenia and disease severity of COVID-19 in type 2 diabetes mellitus. J Diabetes Complications. 35(2):107809.
Roganovi? J. 2021. Downregulation of microRNA-146a in diabetes, obesity and hypertension may contribute to severe COVID-19. Med Hypotheses. 146(11):0-2.
D’Onofrio N, Scisciola L, Sardu C, Trotta MC, De Feo M, Maiello C, et al. 2021. Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte. Cardiovasc Diabetol. 20(1):1-16.
Li G, Chen Z, Lv Z, Li H, Chang D, Lu J. 2021. Diabetes Mellitus and COVID-19: Associations and Possible Mechanisms. Int J Endocrinol.
Ganesan SK, Venkatratnam P, Mahendra J, Devarajan N. 2020. Increased mortality of COVID-19 infected diabetes patients: role of furin proteases. Int J Obes. 44(12):2486-2488.
Adu-Agyeiwaah Y, Grant MB, Obukhov AG. 2020. The Potential Role of Osteopontin and Furin in Worsening Disease Outcomes in COVID-19 Patients with Pre-Existing Diabetes. Cells. 9(11).
American Association of Diabetes. ADA standards of diabetes care 2021. Diabetes Care. 44:S21-S226.
Kementrian Kesehatan Republik Indonesia. 2020. Pedoman Pencegahan Dan Pengendalian COVID-19. 5th ed. Jakarta: Kementrian Kesehatan Republik Indonesia;.
Qi L, Yang Y, Jiang D, Tu C, Wan L, Chen X, et al. 2020. Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study. Int J Infect Dis. 96:531-537.
Ramphul K, Lohana P, Ramphul Y, Park Y, Mejias S, Kaur DB, et al. 2021. Hypertension, diabetes mellitus, and cerebrovascular disease predispose to a more severe outcome of COVID-19. Arch Med Sci - Atheroscler Dis. 6(1):30-39.
Wu J, Zhang J, Sun X, Wang L, Xu Y, Zhang Y, et al. 2020. Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 (COVID-19) infection. Diabetes, Obes Metab. 22(10):1907-1914.
Lisco G, De Tullio A, Giagulli VA, Guastamacchia E, De Pergola G, Triggiani V. 2020. Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review. Endocrine. 70(3):441-453.
Buetti N, Trimboli P, Mazzuchelli T, Lo Priore E, Balmelli C, Trkola A, et al. 2020. Diabetes mellitus is a risk factor for prolonged SARS-CoV-2 viral shedding in lower respiratory tract samples of critically ill patients. Endocrine. 70(3):454-460.
Cano E, Corsini Campioli C, O’Horo JC. 2021. Nasopharyngeal SARS-CoV-2 viral RNA shedding in patients with diabetes mellitus. Endocrine. 71(1):26-27.
Alkundi A, Mahmoud I, Musa A, Naveed S, Alshawwaf M. 2020. Clinical characteristics and outcomes of COVID-19 hospitalized patients with diabetes in the United Kingdom: A retrospective single centre study. Diabetes Res Clin Pract. 165:108263.
DOI: https://doi.org/10.32502/sm.v12i2.3942
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Muhammad Afif Sholehuddin
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
sinta4.png)
